← All patents

US20180215789A1

Concurrent Chemotherapy and Immunotherapy

University of Texas System

Abstract

The concurrent administration of chemotherapy and immunotherapy has been considered a contraindication because of the concern that the induced lymphopenia would ablate therapeutic efficacy of immunotherapy. Temozolomide has been shown to be an effective chemotherapeutic for patients with malignant …

University
University of Texas System
Assignee
Board Of Regents, The University Of Texas System
Inventor
John H. Sampson
Priority date
November 02, 2005
Filing date
March 28, 2018
Publication date
August 02, 2018
Language
en
Metadata fetched
August 29, 2026 00:25